Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Abstract

BackgroundChronic hyperglycemia in type 2 diabetes increases the risk of microvascular events. However, there is continuing uncertainty about its effect on macrovascular outcomes and death. We conducted a meta-analysis of prospective studies to estimate the association of glycosylated hemoglobin level with the risk of all-cause mortality and cardiovascular outcomes among patients with type 2 diabetes.Methodology/Principal FindingsWe systematically searched the MEDLINE database through April 2011 by using Medical Subject Heading search terms and a standardized protocol. We included prospective cohort studies that reported data of glycosylated hemoglobin level on the risk of incident cardiovascular events and all-cause mortality. Relative risk estimates (continuous and categorical variables) were derived or abstracted from each cohort study. Twenty six studies were included in this analysis with a mean follow-up rang of 2.2–16 years. The pooled relative risk associated with a 1% increase in glycosylated hemoglobin level among patients with type 2 diabetes was 1.15 (95% CI, 1.11 to 1.20) for all-cause mortality, 1.17 (95% CI, 1.12 to 1.23) for cardiovascular disease, 1.15 (95% CI, 1.10 to 1.20) for coronary heart disease, 1.11 (95% CI, 1.05 to 1.18) for heart failure, 1.11 (95% CI, 1.06 to 1.17) for stroke, and 1.29 (95% CI, 1.18 to 1.40) for peripheral arterial disease, respectively. In addition, a positive dose-response trend existed between glycosylated hemoglobin level and cardiovascular outcomes.Conclusions/SignificanceChronic hyperglycemia is associated with an increased risk for cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes, likely independently from other conventional risk factors.

Diabetes and Risk of Frailty and Its Potential Mechanisms: A Prospective Cohort Study of Older Adults

“…As an example, results from the Multiple Risk Factor Intervention Trial, with 5,163 diabetic men and 342,815 nondiabetic men followed for an average of 12 years, showed that the absolute risk of coronary mortality for each 20 mg/dl increase in total cholesterol was 3-5 times higher in diabetic than in non-diabetic men (19). Similarly, poor glycemic control is known to increase the risk of long-term complications among diabetic individuals (20,21), with evidence showing that a 1% point elevation in HbA1c concentrations in persons with type 2 diabetes is associated with an approximate 18% increased risk of cardiovascular disease (20) and a 15% increased risk of all-cause mortality (20). Our results suggest that poor glycemic and lipid control may also raise the risk of frailty associated with diabetes mellitus in older adults.…”

A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients

“…Therefore, improved glycaemic control and better management of other identified risk factors for the complications of diabetes and more effective treatment of cardiovascular disease and microvascular complications have resulted in a more optimistic outlook for people with diabetes (3). Zang et al (4) conducted a meta-analysis of prospective studies to estimate the association of glycosylated haemoglobin level with the risk of all-cause mortality and cardiovascular outcomes among patients with type 2 diabetes. They have concluded that chronic hyperglycaemia is associated with an increased risk for cardiovascular outcomes and all-cause of mortality among patients with type 2 diabetes (4).…”

The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease

“…However, most of the cohort studies (3,5) conducted with patients having type 2 diabetes have investigated the relation between glycemic control and cardiovascular disease in patients without vascular disease at baseline.…”